Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.
Tsutomu TakeuchiMasafumi KawanishiMegumi NakanishiHironori YamasakiYoshiya TanakaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
In patients with active RA who received ozoralizumab in combination with MTX, the signs and symptoms of RA were significantly reduced as compared with the outcomes in those receiving placebo. Ozoralizumab demonstrated acceptable tolerability with no new safety signals when compared with other antibodies against tumor necrosis factor.
Keyphrases
- phase ii
- rheumatoid arthritis
- open label
- phase iii
- placebo controlled
- double blind
- clinical trial
- disease activity
- study protocol
- ankylosing spondylitis
- interstitial lung disease
- randomized controlled trial
- type diabetes
- sleep quality
- skeletal muscle
- physical activity
- adipose tissue
- insulin resistance
- systemic sclerosis
- glycemic control